877397-68-7

Usage

Uses

Used in Pharmaceutical Synthesis:
(1S)-1-(2,6-dichloro-3-fluorophenyl)ethyl acetate is used as an intermediate in the synthesis of pharmaceuticals for its versatile properties and reactivity. It plays a crucial role in the development of new drugs and medicines.
Used in Agrochemical Production:
In the agrochemical industry, (1S)-1-(2,6-dichloro-3-fluorophenyl)ethyl acetate is used as a building block in the production of various agrochemicals. Its unique structure and reactivity make it suitable for creating effective and targeted pest control solutions.
Used as a Flavoring Agent:
Due to its aromatic nature, (1S)-1-(2,6-dichloro-3-fluorophenyl)ethyl acetate is used as a flavoring agent in the food and beverage industry. It imparts a distinct taste and aroma to various products, enhancing their overall sensory appeal.
Used as a Fragrance:
(1S)-1-(2,6-dichloro-3-fluorophenyl)ethyl acetate is also utilized as a fragrance in the cosmetics and perfumery industry. Its unique scent profile contributes to the creation of various fragrances and scents for a wide range of consumer products.

Upstream product

• 877399-98-9 C₉H₉Cl₂FO₃S 
• 127-08-2 potassium acetate 
• 877397-67-6 1-(2,6-dichloro-3-fluorophenyl)ethyl acetate 
• 124-63-0 methanesulfonyl chloride 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 330156-50-8 (R)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol 

Downstream Products

• 877397-65-4 (S)‐1‐(2,6-dichloro-3-fluorophenyl)ethanol 

Relevant academic research and scientific papers

CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER

The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.

Inhibitors of nedd8-activating enzyme

The invention relates to an administration unit comprising crystalline form I of {(1 S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.

CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER

The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.

Biotransformation-mediated synthesis of (1S)-1-(2,6-dichloro-3- fluorophenyl)ethanol in enantiomerically pure form

An efficient four-step biotransformation-mediated synthesis of (1S)-1-(2,6-dichloro-3-fluorophenyl)ethanol in enantiomerically pure form is described. This compound is a key intermediate required for the preparation of PF-2341066, a potent inhibitor of c-

Polymorphs of a C-Met/Hgfr Inhibitor

This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.

PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

Compounds of formula (1) are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS

Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.